ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.89▲ +2.41%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Inovio Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Inovio Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Inovio Pharmaceuticals a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.71 and $1.03; in 9 out of 10, between $0.51 and $1.42. Estimated annual volatility is 114%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $120M
- 52-week high
- $2.72
- 52-week low
- $0.56
- Revenue (12 months)
- $0.1M
- Revenue growth (YoY)
- -70.0%
- Gross margin
- 0.0%
- Return on equity
- -409.9%
- Free cash flow (12 months)
- $-33.9M
- Beta
- 1.63
What this means
ATLAS does not publish a fair value for INO right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks INO has traded between $0.56 and $2.72. Today it is 67.2% below that high and 59% above its low.
Its beta is 1.63: it tends to move more than the market, both up and down.
About the company
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases.
Want to see everything about Inovio Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Inovio Pharmaceuticals do?
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases.
What is the chance INO goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, INO ends the month between $0.71 and $1.03.
How big is Inovio Pharmaceuticals and what is its P/E ratio?
Inovio Pharmaceuticals's market capitalization is $120M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is INO?
ATLAS estimates annual volatility at 114%. In a typical month, half of the outcomes end between $0.71 and $1.03.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer